Home » Stocks » CLDX

Celldex Therapeutics, Inc. (CLDX)

Stock Price: $43.75 USD -0.41 (-0.93%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 2.05B
Revenue (ttm) 5.37M
Net Income (ttm) -63.69M
Shares Out 39.61M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $43.75
Previous Close $44.16
Change ($) -0.41
Change (%) -0.93%
Day's Open 43.90
Day's Range 43.63 - 45.16
Day's Volume 338,733
52-Week Range 9.66 - 46.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The short answer: They were impressive.

6 days ago - The Motley Fool

HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offeri...

2 weeks ago - GlobeNewsWire

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

2 weeks ago - Zacks Investment Research

Celldex Therapeutics Inc (NASDAQ: CLDX) has priced an underwritten public offering of around 5.9 million shares at $42.00 per share, representing a discount of about 6% from the last close price of $44....

2 weeks ago - Benzinga

HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares...

2 weeks ago - GlobeNewsWire

The company announced a public stock offering.

2 weeks ago - The Motley Fool

HAMPTON, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditio...

2 weeks ago - GlobeNewsWire

One's a well-known name, while the other has plenty of potential.

Other stocks mentioned: TSLA
2 weeks ago - The Motley Fool

Investors liked Celldex's early stage clinical results.

2 weeks ago - The Motley Fool

Why Focus On Penny Stocks? Here Are A Few That Give A Great Answer To That Question.

Other stocks mentioned: GTBP, MOXC
2 weeks ago - PennyStocks

Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism. The...

2 weeks ago - Benzinga

- 95% complete response rate after single dose of CDX-0159 - - Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief - - Median duration of response 77+ ...

3 weeks ago - GlobeNewsWire

HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company's Phase 1 dose escalation study of PD-L1xCD27 bispecific antib...

1 month ago - GlobeNewsWire

HAMPTON, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antihis...

1 month ago - GlobeNewsWire

HAMPTON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Healthca...

2 months ago - GlobeNewsWire

Celldex (CLDX) delivered earnings and revenue surprises of -31.25% and -39.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

2 months ago - GlobeNewsWire

HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company's growing bispecific platform at the Americ...

3 months ago - GlobeNewsWire

Not at its present valuation, it's not.

3 months ago - The Motley Fool

HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020.

4 months ago - GlobeNewsWire

The biotech reported interim results from a phase 1b study.

4 months ago - The Motley Fool

--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) --  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today repor...

4 months ago - GlobeNewsWire

HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conf...

4 months ago - GlobeNewsWire

Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pr...

5 months ago - Benzinga

--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to e...

5 months ago - GlobeNewsWire

HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healt...

5 months ago - GlobeNewsWire

Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics. Celldex's new pipeline is now made up of 3 Phase 1 immunotherapies/target...

6 months ago - Seeking Alpha

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective...

6 months ago - GlobeNewsWire

These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.

Other stocks mentioned: CODX, CRDF, RVP, VXRT
7 months ago - The Motley Fool

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CODX, CRDF, MCRB, MRNA, NSRGY, NVAX ...
7 months ago - The Motley Fool

HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria...

7 months ago - GlobeNewsWire

HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx C...

8 months ago - GlobeNewsWire

-- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -...

8 months ago - GlobeNewsWire

Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020.

8 months ago - GlobeNewsWire

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Here's why shares of these drugmakers seem unstoppable this year.

Other stocks mentioned: CRDF
9 months ago - The Motley Fool

Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.

9 months ago - Zacks Investment Research

HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind ...

9 months ago - GlobeNewsWire

Why Celldex Has Been A Big Winner In 2020

9 months ago - Seeking Alpha

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare C...

10 months ago - GlobeNewsWire

Here we discuss five biotech companies recording impressive growth so far in 2020.

Other stocks mentioned: ALRN, EBS, HZNP, NVAX
11 months ago - Zacks Investment Research

HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanc...

11 months ago - GlobeNewsWire

Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

--Conference Call and Webcast today at 4:30pm ET-- --Conference Call and Webcast today at 4:30pm ET--

11 months ago - GlobeNewsWire

HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets...

11 months ago - GlobeNewsWire

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for July 9th

Other stocks mentioned: FCX, GAN
1 year ago - Zacks Investment Research

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response... [Read more...]

Industry
Biotechnology
IPO Date
Mar 10, 2008
CEO
Anthony Marucci
Employees
123
Stock Exchange
NASDAQ
Ticker Symbol
CLDX
Full Company Profile

Financial Performance

In 2020, CLDX's revenue was $7.42 million, an increase of 107.61% compared to the previous year's $3.57 million. Losses were -$59.78 million, 17.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is 51.67, which is an increase of 18.10% from the latest price.

Price Target
$51.67
(18.10% upside)
Analyst Consensus: Strong Buy